Vaccinex Reports Third Quarter 2022 Results and Provides Corporate Update
November 14, 2022 08:30 ET
|
Vaccinex, Inc.
Promising initial responses in Phase 1b/2 open-label KEYNOTE B84 study of pepinemab with KEYTRUDA® in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patient enrollment continues in the...
Acumen presents poster describing method to standardize amyloid beta oligomer assays supporting therapeutic development for early Alzheimer’s disease
August 01, 2022 10:30 ET
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va. and CARMEL, Ind., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Scientists at Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) have developed a synthetic model to potentially standardize the...
Vaccinex, Inc. Announces Presentation at the 2022 Alzheimer’s Association International Conference Updating the SIGNAL-AD Study of Pepinemab in Patients with Alzheimer’s Disease
July 29, 2022 07:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., July 29, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Neurodegenerative Diseases Market to reach USD 53 Billion by 2030 and grow steadily at a CAGR of 3.2%: Straits Research
May 27, 2022 11:30 ET
|
Straits Research
New York, United States, May 27, 2022 (GLOBE NEWSWIRE) -- Neurodegenerative diseases are a large and diverse group of disorders characterized by progressive deterioration of the function and...
Comprehensive Analysis in Frontiers in Neuroscience Highlights Acumen Pharmaceuticals’ New Approach to Treating Alzheimer's Disease
April 27, 2022 08:00 ET
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va. and CARMEL, Ind., April 27, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel...
Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2021 and Business Highlights
March 28, 2022 16:05 ET
|
Acumen Pharmaceuticals, Inc.
Acumen is progressing ACU193, the first monoclonal antibody designed to selectively target toxic amyloid-beta oligomers (AβOs) to enter clinical testing Currently enrolling INTERCEPT-AD, a...
Acumen Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on March 28, 2022
March 16, 2022 16:15 ET
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va. and CARMEL, Ind., March 16, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel...
Vaccinex, Inc. to Present at CHDI’s 17th Annual HD Therapeutics Conference Meeting
February 24, 2022 08:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Novartis announces U.S. Court of Appeals for the Federal Circuit (CAFC) upholds validity of Gilenya® (fingolimod) dosage regimen patent
January 04, 2022 01:15 ET
|
Novartis Pharma AG
Basel, January 4, 2022 — Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) issued its decision upholding the validity of US Patent No. 9,187,405 covering a dosing...
Acumen Pharmaceuticals Reports Financial Results for Third Quarter 2021 and Business Highlights
November 15, 2021 08:00 ET
|
Acumen Pharmaceuticals, Inc.
Acumen’s investigational product candidate, ACU193, is the first humanized monoclonal antibody discovered and developed to selectively target toxic amyloid-beta oligomers (AβOs) to enter clinical...